Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Heterogeneity of RCCs Assessed by mpMRI with Direct Radiological-Histopathological Correlation.

Diagnostics (Basel, Switzerland)·2026
Same author

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

European urology·2026
Same author

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

European urology·2026
Same author

Challenges for Developing a Soft Robotics Solution for the Surgical Treatment of Stress Urinary Incontinence in Women.

European urology focus·2026
Same author

Prostate cancer: Value of the PI-FAB score and volume-adjusted PSA density in recurrence assessment after HIFU.

European journal of radiology open·2026
Same author

Letter to the Editor: Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up.

European urology·2026

Related Experiment Video

Updated: Jan 9, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

637

High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes?

Alexander Maurer1, Urs J Muehlematter2, Thibika Sivakumar2

  • 1Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland; alexander.maurer@usz.ch.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|December 4, 2025
PubMed
Summary

Prostate-specific membrane antigen (PSMA) PET scans improved tumor delineation for high-intensity focused ultrasound (HIFU) in prostate cancer (PCa). PSMA PET identified 12% of patients unsuitable for HIFU, potentially improving failure-free survival (FFS) rates.

Keywords:
HIFUPSMA PETfailure-free survivalmpMRIprostate cancertherapy

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.4K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.2K

Related Experiment Videos

Last Updated: Jan 9, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

637
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.4K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.2K

Area of Science:

  • Urology
  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • High-intensity focused ultrasound (HIFU) is a localized ablative therapy for prostate cancer (PCa).
  • Multiparametric MRI (mpMRI) is standard for tumor delineation, but recurrence rates after HIFU can be high (up to 56%).
  • Prostate-specific membrane antigen (PSMA) PET imaging offers potential for improved tumor visualization.

Purpose of the Study:

  • To evaluate recurrence and failure-free survival (FFS) rates in patients undergoing HIFU after PSMA PET imaging.
  • To compare tumor delineation and scoring between PSMA PET and mpMRI for biopsy-proven lesions.

Main Methods:

  • Single-center retrospective cohort study of 26 patients scheduled for HIFU (June 2017-May 2022) with pre-HIFU PSMA PET scans.
  • Patients received primary HIFU or salvage HIFU after radiotherapy for localized PCa or recurrence.
  • FFS defined as absence of International Society of Urological Pathology (ISUP) grade ≥2 on biopsy, imaging progression, or biochemical recurrence.
  • Comparison of tumor detection and scoring (PRIMARY for PSMA PET, PI-RADS 2.1 for mpMRI) for lesions identified within 6 months of HIFU.

Main Results:

  • PSMA PET identified 12% of patients (3/26) as unsuitable for HIFU due to upstaging.
  • Of 23 treated patients, 65% (15/23) were disease-free at a mean follow-up of 3.2 years.
  • PSMA PET demonstrated superior lesion detection compared to mpMRI for 12/23 lesions.
  • Mean PRIMARY score was 4.1, compared to a mean PI-RADS 2.1 score of 3.3.

Conclusions:

  • PSMA PET imaging before HIFU can identify patients unsuitable for treatment, potentially improving outcomes.
  • The study suggests a potential benefit of PSMA PET for tumor delineation, leading to improved FFS rates compared to existing literature.
  • Higher PRIMARY scores on PSMA PET correlate with improved disease control in patients treated with HIFU.